IN8bio CEO to Present at TD Cowen Health Care Conference
Event summary
- IN8bio CEO William Ho to present at TD Cowen Health Care Conference on March 2, 2026.
- Company will highlight latest achievements and upcoming milestones.
- Conference includes one-on-one investor meetings with management.
- Live webcast available via IN8bio's investor relations page.
The big picture
IN8bio's participation in TD Cowen's Health Care Conference underscores its push to engage investors amid a competitive landscape for T cell therapies. The company's focus on γδ T cells positions it within the broader trend of next-generation immuno-oncology treatments, where differentiation and clinical success will be key drivers of valuation.
What we're watching
- Clinical Progress
- How IN8bio's lead programs (INB-100 and INB-200/400) advance through clinical trials.
- Pipeline Development
- The pace at which the novel γδ T cell engager platform (INB-600) moves toward clinical stages.
- Investor Sentiment
- Whether the conference presentation shifts market perception of IN8bio's valuation and growth prospects.
Related topics